December 20, 2009

OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009

BOTHELL, WA and VANCOUVER, BC, Dec. 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009.

A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-747-4649 (U.S. & Canada) or 913-312-1507 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase II clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.

SOURCE: OncoGenex Pharmaceuticals, Inc.

OncoGenex Contact: Scott Cormack, President & CEO, (604) 630-5400,
scormack@oncogenex.com; Media and Investor Contact: Jason Spark, Porter Novelli Life
Sciences, (619) 849-6005, jspark@pnlifesciences.com

Copyright (C) 2009 CNW Group. All rights reserved.

News Provided by COMTEX


Close window | Back to top

Copyright 2018 OncoGenex Pharmaceuticals, Inc.